It’s a great time to be looking for opportunities in biotech as the sector is near the bottom, says MPM Capital’s Dr Christiana Bardon.
Biotech has been in correction over the past eight months
What many see as a sharp decline in biotech, Dr Bardon dubs an overdue correction after a prolonged period of “too much enthusiasm” due to the COVID pandemic. Speaking with CNBC’s Leslie Picker, she said:
The long-term prospects for this industry look as great as ever. The demographics of the aging population means we’ll need new drugs, the support of regulatory environment, and finally the third fundamental is innovation at record high levels.
The iShares Biotech ETF is down 25% from its high in August 2021, but Dr Bardon is focused on the long term. She sees an upward trend in biotech over the next thirty years.
Dr Bardon is particularly interested in Oncology within Biotech
According to the Harvard-trained medical doctor, investors should focus on areas within Biotech that are committed to addressing unmet medical needs, such as Oncology. She added:
Oncology continues to be an exciting area of Biotech. Within Oncology, we’re seeing incredible innovation primarily because of the genomics revolution. And then the regulatory environment is very supportive of cancer drug development.
Dr Bardon sees the U.S. as a global leader in biotech and reiterates that it was this industry that helped the world pull out of the Coronavirus crisis.
The post Is Biotech ripe for investment yet? appeared first on Invezz.
